BRAF inhibitors such as vemurafenib and dabrafenib have been approved to treat BRAF‐mutant melanoma, and are recommended for BRAF‐mutant NSCLC.57, 58, 59. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.